Hironori Fukuda
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 122 publications
Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Journal: Anticancer research
Published: May 18, 2026
Robot-assisted Complete Urinary Tract Exenteration for Multifocal Urothelial Carcinoma: Perioperative Management in Non-dialysis Patients.
Journal: Anticancer research
Published: April 27, 2026
Living-donor Kidney Transplantation After Resection of Mixed Epithelial and Stromal Tumor: A Positive Outcome Despite Not Observing the Recommended Waiting Period.
Journal: Cancer diagnosis & prognosis
Published: April 13, 2026
Real-World Outcomes and Prognostic Factors of Immune Checkpoint Inhibitor Rechallenge for Metastatic Renal Cell Carcinoma: A Multicenter Study.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: March 31, 2026
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
Journal: Targeted oncology
Published: February 28, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.
Journal: International urology and nephrology
Published: February 28, 2026
Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report.
Journal: IJU case reports
Published: February 28, 2026
Pathologic Complete Response After Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial Carcinoma.
Journal: In vivo (Athens, Greece)
Published: January 20, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: January 11, 2026
Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: November 25, 2025
Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy.
Journal: International journal of clinical oncology
Published: November 04, 2025
Last Updated: 09/26/2026